Immix Biopharma Investor Presentation Deck

Preconditioning Regimens Lymphodepletion regimen Frequency Infusion (Day 0) from start of lymphodepletion (days) NXC-201 250 mg cyclophosphamide/m² + 25 mg fludarabine/m² QD, days -5, -4, -3 LO 5 Abecma 300 mg cyclophosphamide/m² + 30 mg fludarabine/m² QD, days -5, -4, -3 LO 5 Source: Berdeja JG, et al. Lancet. 2021; Frigault MJ, et al. Blood Adv. 2023; Munshi NC, et al. N Engl J Med. 2021; Asherie N, et al. Haematologica. 2023 Carvykti 300 mg cyclophosphamide/m² + 30 mg fludarabine/m² QD, days -5, -4, -3 5-7 ●●● IMMIX S BIOPHARMA CART-ddBCMA 300 mg cyclophosphamide/m² + 30 mg fludarabine/m² QD, days -5, -4, -3 LO 5 54

View entire presentation